Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02372136
Other study ID # STU 102014-056
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date December 31, 2023

Study information

Verified date March 2023
Source University of Texas Southwestern Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In preterm infants fed human milk, milk needs to be fortified to meet nutrient recommendations. Fortification can be 1) standard, 2) individualized (adjusted based on daily human milk nutrient analysis and milk volume), or 3) optimized (adjusted based on growth rate and serum analyses). The first specific aim will determine whether individualized and optimized nutrition during hospitalization results in improved growth in the neonatal intensive care unit (NICU) in extremely low gestational age (GA) neonates (ELGANs, <29 weeks) and in small for GA (SGA, birth weight <10th percentile for GA) preterm infants compared with optimized nutrition. The second specific aim will determine whether individualized and optimized nutrition in the NICU improves neurodevelopmental outcomes (acquisition of development milestones) and reduces the risk of disproportionate growth (i.e., excess fat) in the NICU and findings suggestive of metabolic syndrome in the first 3 years of life.


Description:

Hypotheses: 1. Primary hypothesis: In preterm infants (GA <29 weeks or GA <35 weeks and SGA) individualized and optimized nutrition will increase velocity of growth (weight gain velocity by 2 g x kg-1 x day-1 and length velocity by 0.2 cm per week) from birth to 36 weeks of postmenstrual age (GA plus postnatal age) or discharge (whichever comes first) in comparison with optimized nutrition. 2. Secondary hypotheses: Individualized and optimized nutrition will improve neurodevelopmental outcome and reduce the risk of disproportionate growth (excess fat) in the NICU and findings suggestive of metabolic syndrome in the first 3 years of life. Study design: Double-blinded randomized controlled trial (RCT): After consent, 150 neonates will be randomized to one of two groups. Study intervention: Patients will be randomized to either: 1. Control: optimized nutrition: Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen and albumin and velocity of growth (weight and length). 2. Intervention: Individualized and optimized nutrition: Milk fortification will be optimized as in control neonates. In addition, nutrition will be individualized every day. Milk fortification will be adjusted based on daily measurements of macronutrients in human milk using near-infrared analysis. Randomization will be done by computer provided by a statistician using random block allocation and stratification by GA and size for age (AGA [appropriate for GA] 23-28 weeks, SGA 23-28 weeks and SGA 29-34 weeks). Twins and multiples will be randomized to the same arm of the study.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 120
Est. completion date December 31, 2023
Est. primary completion date February 4, 2020
Accepts healthy volunteers No
Gender All
Age group N/A to 7 Days
Eligibility Inclusion Criteria: - Preterm infants <29 weeks GA and SGA infants <35 weeks GA born at Parkland Health and Hospital System - Maternal plan to breastfeed or to use milk from the donor milk bank - From birth to 1 week of life Exclusion Criteria: - Patients on comfort care only - Patients with major congenital abnormalities - Patients who are too unstable for the first 7 days to have an accurate length measurement

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Individualized Nutrition
Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis. In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas. In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91).
Optimized nutrition
Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).

Locations

Country Name City State
United States UT Southwestern Medical Center Dallas Texas

Sponsors (3)

Lead Sponsor Collaborator
University of Texas Southwestern Medical Center Children's Medical Center Dallas, The Gerber Foundation

Country where clinical trial is conducted

United States, 

References & Publications (1)

Brion LP, Rosenfeld CR, Heyne R, Brown LS, Lair CS, Petrosyan E, Jacob T, Caraig M, Burchfield PJ. Optimizing individual nutrition in preterm very low birth weight infants: double-blinded randomized controlled trial. J Perinatol. 2020 Apr;40(4):655-665. doi: 10.1038/s41372-020-0609-1. Epub 2020 Feb 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Mortality Percent of infants who died from birth to discharge from the neonatal intensive care unit Until discharge from the neonatal intensive care unit
Other Necrotizing Enterocolitis Percentage of infants who developed necrotizing enterocolitis stage II or greater (using the modified Bell stage classification) in the neonatal intensive care unit Until discharge from the neonatal intensive care unit
Primary Growth Velocity Rate of weight gain [g x kg-1 x day-1] and length velocity [cm x week-1] 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Primary Linear Growth Velocity Increase in body length per week from birth to 36 weeks postmenstrual age or discharge 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Disproportionate Growth (Increased Fat Mass): BMI >90th Centile Disproportionate growth (increased fat mass): BMI > 90th centile for sex and age 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Blood Pressure Systolic blood pressure (calm or sleeping) 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Hypertension Systolic blood pressure beyond limit defined by the SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN at 1-3 years of age
Secondary Neurodevelopment Bayley Scale of Infant and Toddler Development, Third Edition (BSID-III): cognitive composite score Higher scores mean a better outcome. The composite scaled score has a mean of 100 and a SD of 15, a floor of 55 and a ceiling of 145.
Bayley, N. (2006). Bayley Scales of Infant and Toddler Development- Third Edition. San Antonio, TX: Harcourt Assessment.
DOI: 10.1177/0734282906297199
18-41 months adjusted age (postnatal age corrected for prematurity)
Secondary Neurodevelopment Bayley Scale of Infant and Toddler Development, Third Edition (BSID-III): language composite score Higher scores mean a better outcome. The composite scaled score has a mean of 100 and a SD of 15, a floor of 47 and a ceiling of 153.
Bayley, N. (2006). Bayley Scales of Infant and Toddler Development- Third Edition. San Antonio, TX: Harcourt Assessment.
DOI: 10.1177/0734282906297199
18-41 months adjusted age (postnatal age corrected for prematurity) 18-41 months adjusted age (postnatal age corrected for prematurity) 18-41 months corrected age 18-41 months
Secondary Assessment of Biomarkers of Adiposity Serum levels of adipokines: leptin, adiponectin and resistin at 1-3 years of age
Secondary Assessment of Renal Glomerular Function Assessment of renal glomerular function: Serum level of cystatin C at 1-3 years of age
Secondary Comparison of Weight With Expected Value for Age and Gender Comparison of weight with expected value for age and gender: Z score for weight 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Comparison of Length With Expected Value for Age and Gender Comparison of length with expected value for age and gender: Z score for length 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Comparison of Head Size With Expected Value for Age and Gender Comparison of head size with expected value for age and gender: Z score for fronto-occipital circumference 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Comparison of Rate of Weight Gain With Expected Value for Age and Gender Comparison of rate of weight gain with expected value for age and gender: change in z score for weight from birth to time frame 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Comparison of Rate of Linear Growth With Expected Value for Age and Gender Comparison of rate of linear growth with expected value for age and gender: Change in z score for length from birth to time frame 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Comparison of Rate of Head Growth With Expected Value for Age and Gender Change in z score for fronto-occipital circumference from birth to time frame 36 (range 35-37) weeks postmenstrual age or discharge (whichever comes first)
Secondary Body Composition Percent fat mass measured by Dexascan at 1 year of age and 3 years of age
See also
  Status Clinical Trial Phase
Recruiting NCT05030337 - Optimising Ventilation in Preterms With Closed-loop Oxygen Control N/A
Completed NCT02916914 - Impact of Feeding Interval of Preterms on the Time of Transition From Tube Feeding to Oral Feeding N/A
Not yet recruiting NCT06335524 - Infant-Maternal Partnership and Cognitive Training Study for Preterm Infants N/A
Completed NCT02391389 - VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping N/A
Completed NCT00419588 - Growth of Airways and Lung Tissues in Premature and Healthy Infants
Completed NCT05217186 - Associations Between Early Neonatal Neuroimaging, Hammersmith Infant Neurological Examination and General Movements
Completed NCT04886310 - Peabody Developmental Motor Scale-2 in 0 - 24 Months in Turkey
Enrolling by invitation NCT04478487 - Novel Human Milk Based Human Milk Fortifier N/A
Not yet recruiting NCT05592431 - Effect of Volume Guarantee-High Frequency Oscillatory Ventilation on Cerebral Blood Flow in Neonates N/A
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Completed NCT04889846 - The Effects of SAFE Early Intervention Approach in Premature Infants in Turkey N/A
Recruiting NCT04064398 - Evaluation of Gastric Residuals and Feedings Progression N/A
Completed NCT04500353 - Routine Or Selective Application of a Face Mask for Preterm Infants at Birth: the ROSA Trial N/A
Completed NCT04247308 - Multi Modal Stimulations in Pre-term Neonates N/A
Completed NCT03860142 - Evolution of Food Orality in Children Aged Between 24 and 36 Months: Comparison of the Severity and Specificities of Disorders Between Two Populations of Children, Born Very Prematurely and Born at Term
Completed NCT04234152 - Complete Shielding of Multivitamins to Reduce Toxic Peroxides in the Parenteral Nutrition: A Pilot Study N/A
Terminated NCT04641000 - The Alberta BLOOM Long Term Follow Up Study
Completed NCT04284891 - Critical Respiratory Diseases in Ex-preterm Infants in PICU
Completed NCT04327466 - Effect of High Frequency Oscillatory Highflow Nasal Cannula on Desaturations and Bradycardia in Preterm Infants N/A
Completed NCT00062452 - Esophageal Motility and Airway Defenses Among Infants N/A

External Links